Leukemia Posts on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Evaluating the impact of stopping early venetoclax treatment in patients with relapsed/refractory chronic lymphocytic leukemia

Evaluating the impact of stopping early venetoclax treatment in patients with relapsed/refractory chronic lymphocytic leukemia

Posted by on Feb 28, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the impact of venetoclax (Venclexta) modification or early treatment ending on the outcomes of patients with relapsed/refractory chronic lymphocytic leukemia (CLL).  This study concluded that venetoclax treatment modification did not impact outcomes but the early ending of...

Read More

Allogenic versus autologous hematopoietic stem cell transplant for patients with acute promyelocytic leukemia

Allogenic versus autologous hematopoietic stem cell transplant for patients with acute promyelocytic leukemia

Posted by on Feb 28, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to compare the outcomes of allogeneic (allo) and autologous (auto) hematopoietic stem cell transplant (HSCT) for patients with acute promyelocytic leukemia (APL) in second complete remission (CR2).  This study concluded that autoHSCT resulted in better outcomes for these patients.   Some background...

Read More

Comparing treosulfan and busulfan based conditioning treatment for patients with acute myeloid leukemia before transplant

Comparing treosulfan and busulfan based conditioning treatment for patients with acute myeloid leukemia before transplant

Posted by on Feb 26, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term survival outcomes of treosulfan (Trecondi)-based versus busulfan (Myleran)-based conditioning treatment in patients with acute myeloid leukemia. This study concluded that treosulfan-based conditioning treatment may have better outcomes for these patients.   Some background...

Read More

Does tyrosine kinase inhibitors dose reduction influence the outcomes of patients with in chronic myeloid leukemia?

Does tyrosine kinase inhibitors dose reduction influence the outcomes of patients with in chronic myeloid leukemia?

Posted by on Jan 31, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effect of tyrosine kinase inhibitor (TKI) dose reduction in patients with chronic myeloid leukemia (CML) after achieving a major molecular response (MMR).   This study concluded that the TKI dose reduction was safe and effective for the majority of these...

Read More

Evaluating the gimema LAL-1308 treatment protocol for adolescent and young adult patients with acute lymphoblastic leukemia

Evaluating the gimema LAL-1308 treatment protocol for adolescent and young adult patients with acute lymphoblastic leukemia

Posted by on Jan 31, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the GIMEMA LAL-1308 treatment protocol in young patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.   This study concluded that this treatment protocol was safe and effective for these patients.  Some background Adolescents and young adults...

Read More

Total body irradiation vs chemotherapy conditioning in children with acute lymphoblastic leukemia

Total body irradiation vs chemotherapy conditioning in children with acute lymphoblastic leukemia

Posted by on Jan 17, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if chemotherapy (CT) conditioning could replace total body irradiation (TBI) before stem cell transplant (SCT) in children with acute lymphoblastic leukemia (ALL).  This study concluded that TBI in combination with CT was safer and more effective than CT conditioning alone in these...

Read More

Dasatinib and blinatumomab for patients with Philadelphia chromosome positive acute lymphoblastic leukemia

Dasatinib and blinatumomab for patients with Philadelphia chromosome positive acute lymphoblastic leukemia

Posted by on Jan 4, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the combination of dasatinib (Sprycel) and blinatumomab (Blincyto) as a first-line therapy in patients with Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL).  This study concluded that this treatment combination led to better response and survival in these...

Read More

The effect of chemotherapy dose intensity on outcomes for patients with aggressive adult T-cell leukemia/lymphoma

The effect of chemotherapy dose intensity on outcomes for patients with aggressive adult T-cell leukemia/lymphoma

Posted by on Jan 4, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effect of chemotherapy dose intensity on outcomes for patients with adult T-cell leukemia/lymphoma.   This study concluded that higher chemotherapy dose intensity improves outcomes for these patients.  Some background Adult T-cell leukemia/lymphoma (ATL) is an aggressive blood cancer. It...

Read More